Winslow Evans & Crocker’s Tvardi Therapeutics TVRD Stock Holding History

Winslow Evans & Crocker’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$41K	Sell	74 -5	-6%	-$2.62K	0.01%	643
2020 Q3	$36K	Hold	79	–	–	0.01%	520
2020 Q2	$48K	Hold	79	–	–	0.01%	469
2020 Q1	$38K	Hold	79	–	–	0.01%	475
2019 Q4	$46K	Hold	79	–	–	0.01%	520
2019 Q3	$52K	Sell	79 -4	-5%	-$3.33K	0.01%	493
2019 Q2	$66K	Sell	83 -8	-9%	-$5.62K	0.02%	466
2019 Q1	$66K	Hold	91	–	–	0.02%	447
2018 Q4	$44K	Hold	91	–	–	0.01%	484
2018 Q3	$80K	Sell	91 -83	-48%	-$59.9K	0.02%	409
2018 Q2	$122K	Hold	174	–	–	0.04%	336
2018 Q1	$77.7K	Buy	174 +155	+816%	+$75.2K	0.03%	399
2017 Q4	$8.32K	Hold	19	–	–	﹤0.01%	842
2017 Q3	$9.31K	Hold	19	–	–	﹤0.01%	834
2017 Q2	$10.5K	Hold	19	–	–	﹤0.01%	906
2017 Q1	$12.5K	Buy	+19	New	+$10.2K	﹤0.01%	837

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Winslow Evans & Crocker's TVRD Position: Q4 2020 in Review

Winslow Evans & Crocker reduced its Tvardi Therapeutics (TVRD) stake by 6.3% in Q4 2020, selling an estimated $2.62K and leaving 74 shares worth $41K. The position accounts for 0.01% of the portfolio, ranked #643.

Winslow Evans & Crocker first reported a position in TVRD in Q1 2017 and has held it in 16 quarters since. The position peaked at $122K in Q2 2018. 155 funds tracked by Wall St. Rank hold TVRD as of Q4 2020.

Winslow Evans & Crocker held 74 shares of Tvardi Therapeutics worth $41K as of Q4 2020.
Winslow Evans & Crocker sold 5 Tvardi Therapeutics shares in Q4 2020, an estimated $2.62K.
Tvardi Therapeutics made up 0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #643 holding.
Winslow Evans & Crocker first reported a position in Tvardi Therapeutics in Q1 2017 and has held it in 16 quarters since.
Winslow Evans & Crocker's Tvardi Therapeutics position peaked at $122K in Q2 2018.
155 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.